Fundamentals-based quality & risk · not a recommendation
Vivimed Labs Ltd scores 5/100 (Avoid) on the Orion Score — poor business quality (4), poor growth (6) and poor balance-sheet safety (3). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
65/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q3 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q3 2026 | ₹15.99 | ₹-16.55 | -97.3% | ₹-2.00 |
| Q2 2026 | ₹20.61 | ₹-7.3 | -28.4% | ₹-0.88 |
| Q1 2026 | ₹21.39 | ₹-5.49 | -24.7% | ₹-0.66 |
| Q4 2025 | ₹25.61 | ₹-5.6 | -14.4% | — |
| Q3 2025 | ₹36.51 | ₹-5.97 | -15.2% | ₹-0.72 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹116.27 | ₹-31.96 | ₹-9.89 | -24.9% |
| FY 2024 | ₹149.07 | ₹-45.45 | ₹-24.67 | -13.8% |
| FY 2023 | ₹187.1 | ₹-328.54 | ₹-187.24 | -109.9% |
| FY 2022 | ₹236.57 | ₹-67.65 | ₹-8.01 | -11.0% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| VIVIMEDLAB ★ | ₹53 Cr | — | -5.66% | — | — | -97.25% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹88,148 Cr | 25.39 | 12.55% | 9.93% | 0.21x | 15.11% |
| ASTERDM | ₹68,390 Cr | 104.34 | 8.93% | 10.07% | 0.46x | 13.98% |
| ABBOTINDIA | ₹59,509 Cr | 38.28 | 36.31% | 34.46% | 0.04x | 27.01% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹920.83 | ₹950.91 | ₹995.05 | ₹1,266.02 |
| Equity | ₹-35.17 | ₹-5.46 | ₹39.42 | ₹364.29 |
| Total Debt | ₹376.33 | ₹378.79 | ₹381.03 | ₹358.88 |
| Cash | ₹0.71 | ₹1.63 | ₹3.76 | ₹7.18 |
| Net Debt | ₹375.62 | ₹375.3 | ₹374.8 | ₹351.7 |
| Working Capital | ₹-80.64 | ₹-67.74 | ₹-85.1 | ₹133.87 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 16.75% ↑ | 5.96% ↑ | 4.88% | 72.41% ↓ |
| Q3 FY2026 | 7.76% | 1.64% | — | 90.47% |
| Q2 FY2026 | 7.76% | 1.64% | — | 90.47% |
| Q1 FY2026 | 7.76% ↓ | 1.64% | — | 90.47% ↑ |
| Q4 FY2025 | 20.94% | 1.64% | — | 77.3% |
| Q3 FY2025 | 20.94% | 1.64% | — | 77.3% |
| Q2 FY2025 | 20.94% | 1.64% | — | 77.3% |
| Q1 FY2025 | 20.94% | 1.64% | — | 77.3% |
No recent corporate actions
Ask: "Is Vivimed Labs Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.